Jaguar Health Inc Dossier
Qualitative Analysis
Business overview
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products sustainably sourced from plants in rainforest areas for both human prescription use and veterinary use. The company's lead human product is Mytesi (crofelemer), which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar Health operates through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., and is actively expanding its clinical pipeline of crofelemer for rare and orphan diseases, including microvillus inclusion disease (MVID) and short bowel syndrome (SBS). Additionally, the company operates Magdalena Biosciences, a joint venture with Filament Health Corp, focused on plant-derived prescription medicines for mental health indications.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In January 2026, Jaguar out-licensed the exclusive U.S. commercialization rights for Mytesi and conditionally approved Canalevia-CA1 to Future Pak, LLC (via its affiliate Woodward Specialty, LLC). This strategic shift transitions Jaguar from direct commercialization to a manufacturing and supply model, allowing the company to focus resources on its rare-disease pipeline.
Expected impact: Brings in $16 million upfront, an additional $3 million from terminating a buy-back provision in March 2026, and up to $20 million in future milestone payments, while significantly reducing sales and marketing overhead.
Through its joint venture Magdalena Biosciences, Jaguar is evaluating a novel whole-leaf coca extract (MB2500) as a prescription drug candidate under FDA Botanical Guidance for post-GLP-1 weight loss management and weight gain prevention.
Expected impact: Addresses a major unmet medical need for patients who discontinue GLP-1 therapies and experience rebound weight gain.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Highly critical. It provides immediate non-dilutive capital to fund Jaguar's rare-disease clinical programs and shifts the commercialization burden of Mytesi and Canalevia-CA1 to an experienced HIV-focused commercial organization.
Terms: $18 million upfront ($16 million paid at closing, $2 million contingent on post-closing conditions), an additional $3 million paid in March 2026 to terminate the buy-back provision, and up to $20 million in future milestone payments. Jaguar retains manufacturing rights and receives manufacturing revenue.
Expands Jaguar's botanical drug development capabilities into mental health, CNS, and weight management indications by leveraging Jaguar's medicinal plant library and Filament's technology.
Terms: Magdalena Biosciences is approximately 40% owned by Jaguar Health and is funded by a $1,000,000 commitment from One Small Planet.